Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 ...
Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...
Deep dive into the challenges and opportunities of India's Blue Economy. Learn about the Deep Ocean Mission, the risks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback